

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.

Multichannel Intraluminal Esophageal Impedance with pH Monitoring

MP9567

Covered Service: Yes

Prior Authorization Required: See [Gastrointestinal Monitoring System \(Smart Pill®\) MP9707](#) for additional information.

Additional Information: None

Prevea360 Health Plan Medical Policy:

- 1.0 Multichannel intraluminal esophageal impedance with pH monitoring for evaluation of gastroesophageal reflux disease (GERD) **does not** require prior authorization and is considered medically necessary in members non-responsive to treatment or with atypical symptoms.
- 2.0 Multichannel intraluminal esophageal impedance with pH monitoring is considered experimental and investigational and therefore not medically necessary for all other indications.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	July 20, 2022
Revised:	Medical Policy Committee/Health Services Division	February 21, 2024
Reviewed:	Medical Policy Committee/Health Services Division	July 19, 2023
	Medical Policy Committee/Health Services Division	February 21, 2024

Published: 03/01/2024

Effective: 03/01/2024